S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
NASDAQ:CMRX

Chimerix - CMRX Stock Forecast, Price & News

$1.82
-0.01 (-0.55%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.79
$1.85
50-Day Range
$1.70
$2.35
52-Week Range
$1.27
$6.43
Volume
500,645 shs
Average Volume
638,874 shs
Market Capitalization
$160.23 million
P/E Ratio
1.04
Dividend Yield
N/A
Price Target
$8.50

Chimerix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
367.0% Upside
$8.50 Price Target
Short Interest
Healthy
3.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.49
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$5,685 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $1.97 to ($0.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

193rd out of 1,029 stocks

Pharmaceutical Preparations Industry

83rd out of 504 stocks

CMRX stock logo

About Chimerix (NASDAQ:CMRX) Stock

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Stock News Headlines

Why Chimerix (CMRX) Stock Is Tanking Today
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Hedge fund urges Durham drugmaker Chimerix to liquidate
Chimerix Responds to Rubric Capital Management
Buy 3 of the Best Stocks by Using Net Income Ratio
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Chimerix (CMRX) Beats Q3 Earnings Estimates
See More Headlines
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Company Calendar

Last Earnings
11/04/2021
Today
2/07/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMRX
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+367.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-173,240,000.00
Pretax Margin
465.22%

Debt

Sales & Book Value

Annual Sales
$1.98 million
Book Value
$0.79 per share

Miscellaneous

Free Float
80,825,000
Market Cap
$160.23 million
Optionable
Optionable
Beta
1.15

Key Executives

  • Michael A. Sherman
    President, Chief Executive Officer & Director
  • Michael T. Andriole
    Chief Financial & Business Officer
  • Randall Lanier
    Chief Scientific Officer
  • Roy W. Ware
    Chief Technology & Manufacturing Officer
  • Caryn Barnett
    Vice President-Clinical Operations













CMRX Stock - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings
or view top-rated stocks.

What is Chimerix's stock price forecast for 2023?

3 brokerages have issued 1 year price targets for Chimerix's shares. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they predict the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 367.0% from the stock's current price.
View analysts price targets for CMRX
or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2023?

Chimerix's stock was trading at $1.86 at the start of the year. Since then, CMRX shares have decreased by 2.2% and is now trading at $1.82.
View the best growth stocks for 2023 here
.

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our CMRX earnings forecast
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.39 million. Chimerix had a net margin of 464.75% and a trailing twelve-month return on equity of 147.04%. During the same quarter last year, the business posted ($0.18) EPS.

What other stocks do shareholders of Chimerix own?
What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Monaco Asset Management SAM (2.62%), Allspring Global Investments Holdings LLC (0.43%), Assenagon Asset Management S.A. (0.30%), Strs Ohio (0.09%), Mission Wealth Management LP (0.04%) and Envestnet Asset Management Inc. (0.03%). Insiders that own company stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends
.

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $1.82.

How much money does Chimerix make?

Chimerix (NASDAQ:CMRX) has a market capitalization of $160.23 million and generates $1.98 million in revenue each year. The biopharmaceutical company earns $-173,240,000.00 in net income (profit) each year or $1.75 on an earnings per share basis.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.

This page (NASDAQ:CMRX) was last updated on 2/8/2023 by MarketBeat.com Staff